Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Depreciation & Amortization (CF) (2016 - 2019)

Syndax Pharmaceuticals (SNDX) has 5 years of Depreciation & Amortization (CF) data on record, last reported at -$176000.0 in Q3 2019.

  • For Q3 2019, Depreciation & Amortization (CF) fell 21.38% year-over-year to -$176000.0; the TTM value through Jun 2020 reached -$176000.0, up 67.94%, while the annual FY2025 figure was $6.0 million, 25.0% down from the prior year.
  • Depreciation & Amortization (CF) reached -$176000.0 in Q3 2019 per SNDX's latest filing, up from -$224000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $190000.0 in Q3 2015 and bottomed at -$224000.0 in Q2 2019.
  • Average Depreciation & Amortization (CF) over 5 years is -$12266.7, with a median of $4000.0 recorded in 2016.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 1725.0% in 2017, then tumbled 1133.33% in 2018.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $190000.0 in 2015, then crashed by 136.32% to -$69000.0 in 2016, then surged by 323.19% to $154000.0 in 2017, then plummeted by 194.16% to -$145000.0 in 2018, then decreased by 21.38% to -$176000.0 in 2019.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were -$176000.0 in Q3 2019, -$224000.0 in Q2 2019, and -$180000.0 in Q1 2019.